Loading...
Market
Will Benralizumab be included in GINA guidelines by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
GINA official publications and updates
Story
Benralizumab: First New Asthma Treatment in 50 Years Reduces Need for Further Treatment by 30%
Nov 28, 2024, 05:44 AM
A significant advancement in asthma and COPD treatment has emerged with the development of a new drug, benralizumab, which has shown to be more effective than traditional steroid tablets during acute attacks. This monoclonal antibody, targeting interleukin-5 receptor-α, was tested in a double-blind, double-dummy, active placebo-controlled randomized trial by King's College London. The study, published in The Lancet Respiratory Medicine, found that benralizumab reduced the need for further treatment by 30% compared to steroids. This breakthrough is being hailed as a 'game-changer' by doctors and patients, marking the first new treatment for asthma attacks in over 50 years.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 20% reduction • 25%
20% to 30% reduction • 25%
31% to 40% reduction • 25%
More than 40% reduction • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%